An open label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin and dexamethasone in newly diagnosed myeloma

We conducted a phase 1/2 trial evaluating the combination of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone (CVDD) for newly diagnosed multiple myeloma (MM). The primary objective of the phase 1 was to evaluate the safety and tolerability of maximum planned dose (MP...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Haematol
Main Authors: Nishihori, Taiga, Baz, Rachid, Shain, Kenneth, Kim, Jongphil, Ochoa-Bayona, Jose L., Yue, Binglin, Sullivan, Daniel, Dalton, William, Alsina, Melissa
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4508238/
https://ncbi.nlm.nih.gov/pubmed/25600676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.12509
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados